NASDAQ:BABY - Natus Medical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$32.47 +0.38 (+1.18 %)
(As of 12/13/2018 03:37 AM ET)
Previous Close$32.09
Today's Range$32.39 - $32.93
52-Week Range$27.69 - $41.55
Volume207,800 shs
Average Volume348,059 shs
Market Capitalization$1.13 billion
P/E Ratio22.39
Dividend YieldN/A
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. It offers diagnostic electroencephalography (EEG), ambulatory EEG, and long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, intra-operative monitoring, and diagnostic and monitoring transcranial doppler ultrasound technology systems. The company also provides hearing screening products to screen the hearing; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. In addition, it offers jaundice management products to treat jaundice; brain injury products to diagnose the severity of brain injury; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); and essential products used in the everyday operation of NICU. Further, the company provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in Pleasanton, California.

Receive BABY News and Ratings via Email

Sign-up to receive the latest news and ratings for BABY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:BABY
Previous Symbol


Debt-to-Equity Ratio0.23
Current Ratio2.62
Quick Ratio1.89


Trailing P/E Ratio22.39
Forward P/E Ratio21.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$500.97 million
Price / Sales2.19
Cash Flow$2.4304 per share
Price / Cash Flow13.36
Book Value$13.55 per share
Price / Book2.40


EPS (Most Recent Fiscal Year)$1.45
Net Income$-20,290,000.00
Net Margins-3.53%
Return on Equity11.34%
Return on Assets6.93%


Outstanding Shares33,780,000
Market Cap$1.13 billion

Natus Medical (NASDAQ:BABY) Frequently Asked Questions

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "BABY."

How will Natus Medical's stock buyback program work?

Natus Medical declared that its board has approved a share repurchase plan on Thursday, February 22nd 2018, which allows the company to repurchase $30,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board believes its stock is undervalued.

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) issued its quarterly earnings results on Wednesday, October, 24th. The medical equipment provider reported $0.40 EPS for the quarter, missing analysts' consensus estimates of $0.42 by $0.02. The medical equipment provider had revenue of $130.60 million for the quarter, compared to the consensus estimate of $132.92 million. Natus Medical had a negative net margin of 3.53% and a positive return on equity of 11.34%. The business's revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.40 earnings per share. View Natus Medical's Earnings History.

When is Natus Medical's next earnings date?

Natus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Natus Medical.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical issued an update on its FY 2018 earnings guidance on Wednesday, October, 24th. The company provided EPS guidance of $1.47-1.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.55. The company issued revenue guidance of $525-530 million, compared to the consensus revenue estimate of $530.21 million.Natus Medical also updated its Q4 guidance to $0.48-0.51 EPS.

What price target have analysts set for BABY?

3 analysts have issued 12-month price objectives for Natus Medical's stock. Their forecasts range from $36.00 to $49.00. On average, they anticipate Natus Medical's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price. View Analyst Price Targets for Natus Medical.

What is the consensus analysts' recommendation for Natus Medical?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natus Medical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natus Medical.

Has Natus Medical been receiving favorable news coverage?

Media coverage about BABY stock has been trending neutral on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Natus Medical earned a news impact score of 0.3 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days.

Who are some of Natus Medical's key competitors?

Who are Natus Medical's key executives?

Natus Medical's management team includes the folowing people:
  • Mr. Jonathan A. Kennedy, Pres, CEO & Director (Age 47)
  • Dr. D. Christopher Chung, VP of Medical Affairs, Quality & Regulatory Affairs (Age 54)
  • Mr. Austin F. Noll III, VP & GM of Neurology SBU (Age 51)
  • Mr. Benjamin Drew Davies, Exec. VP & CFO (Age 52)
  • Mr. Carsten Buhl, Pres & CEO of Otometrics SBU (Age 45)

Who are Natus Medical's major shareholders?

Natus Medical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.84%), Janus Henderson Group PLC (9.21%), Vanguard Group Inc. (7.73%), Eagle Asset Management Inc. (5.70%), Dimensional Fund Advisors LP (4.78%) and Confluence Investment Management LLC (2.61%). Company insiders that own Natus Medical stock include Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical.

Which major investors are selling Natus Medical stock?

BABY stock was sold by a variety of institutional investors in the last quarter, including Beddow Capital Management Inc., Confluence Investment Management LLC, Strs Ohio, JPMorgan Chase & Co., JPMorgan Chase & Co., Teachers Retirement System of The State of Kentucky, Bank of New York Mellon Corp and Olstein Capital Management L.P.. Company insiders that have sold Natus Medical company stock in the last year include Dong Chune Christopher Chung, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Robert A Gunst and William M Moore. View Insider Buying and Selling for Natus Medical.

Which major investors are buying Natus Medical stock?

BABY stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Rutabaga Capital Management LLC MA, BlackRock Inc., Morgan Stanley, Eagle Asset Management Inc., Fenimore Asset Management Inc., Vanguard Group Inc. and WCM Investment Management CA. View Insider Buying and Selling for Natus Medical.

How do I buy shares of Natus Medical?

Shares of BABY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natus Medical's stock price today?

One share of BABY stock can currently be purchased for approximately $32.47.

How big of a company is Natus Medical?

Natus Medical has a market capitalization of $1.13 billion and generates $500.97 million in revenue each year. The medical equipment provider earns $-20,290,000.00 in net income (profit) each year or $1.45 on an earnings per share basis. Natus Medical employs 1,726 workers across the globe.

What is Natus Medical's official website?

The official website for Natus Medical is

How can I contact Natus Medical?

Natus Medical's mailing address is 6701 KOLL CENTER PARKWAY SUITE 120, PLEASANTON CA, 94566. The medical equipment provider can be reached via phone at 925-223-6700 or via email at [email protected]

MarketBeat Community Rating for Natus Medical (NASDAQ BABY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Natus Medical and other stocks. Vote "Outperform" if you believe BABY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BABY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel